17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer

• Tove Sivik ,

  * E-mail: tove.sivik@liu.se

  Affiliation Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden

  ⨯
• Cecilia Gunnarsson,

  Affiliations Division of Clinical Genetics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden, County Council of Östergötland, Linköping, Sweden

  ⨯
• Tommy Fornander,

  Affiliation Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

  ⨯
• Bo Nordenskjöld,

  Affiliations Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden, County Council of Östergötland, Linköping, Sweden

  ⨯
• Lambert Skoog,

  Affiliation Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

  ⨯
• Olle Stål,

  Affiliations Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden, County Council of Östergötland, Linköping, Sweden

  ⨯
• Agneta Jansson

  Affiliation Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden

  ⨯